LUNG PERFUSION WITH CHEMOTHERAPEUTIC AGENTS

New chemotherapeutic agents for non-small cell lung cancer.

The identification of new chemotherapeutic agents for the treatment of non-small cell lung cancer should proceed in a structured, logical fashion. Agents should be evaluated on the basis of multiple objective and subjective end points. A 15% or greater major objective response rate, demonstrated in multiple single-agent phase II trials, is considered the lower limit for an agent to be deemed cl...

PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation.

PURPOSE Lung cancer, the leading cause of cancer mortality worldwide, is often diagnosed at late stages and responds poorly to conventional therapies, including chemotherapy and irradiation. A great majority of lung tumors are defective in the p53 pathway, which plays an important role in regulating apoptotic response to anticancer agents. PUMA was recently identified as an essential mediator o...

Evaluation of Chemotherapeutic Agents

This fourth, thoroughly revised, edition of Calmette's well-known manual aims to bring together the maximum of information which will be of value to the bacteriologist in his daily work. It is based largely on the techniques utilized at the Pasteur Institute in Paris. The topics included differ from those found in similar manuals in this country which are usually texts of laboratory diagnosis a...

Enzymes as Chemotherapeutic Agents

Effect of chemotherapeutic agents on chromosomes of patients with lung cancer.

in leukocytes both in vivo and in vitro. Similar studies have been carried out on the in vitro effect of chemotherapeutic drugs; however, relatively few studies have been reported on the in vivo effect of chemotherapeutic drugs on chromosomes.’11 Of the latter group, there were only three cases of bronchogenic carcinoma, all treated with nitrogen mustard.2’9 This study reports chromosome change...